Goldman Sachs Assumes Spring Works Therapeutics (SWTX) at Buy

March 22, 2021 7:36 AM EDT
Get Alerts SWTX Hot Sheet
Price: $74.80 +2.69%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Goldman Sachs analyst Corinne Jenkins assumes coverage on Spring Works Therapeutics (NASDAQ: SWTX) with a Buy rating and a price target of $112.00.

The analyst commented, "Momentum building across portfolio with four catalysts expected in 2021. We assume coverage of SWTX from Paul Choi with a Buy rating and 12-month price target of $112, driven primarily by our positive bias ahead of four clinical catalysts in 2021. "

For an analyst ratings summary and ratings history on Spring Works Therapeutics click here. For more ratings news on Spring Works Therapeutics click here.

Shares of Spring Works Therapeutics closed at $68.20 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Goldman Sachs